George Clinical, an Australian-based, global, scientifically-backed clinical research organization (CRO) has significantly expanded its capabilities in Taiwan, having been granted a license to import drugs into the country for clinical trials on behalf of sponsors. This milestone will be of particular benefit to small to mid-sized clinical trial clients who do not have an entity in Taiwan by simplifying and accelerating their path to an operational drug study.
CROs without such a license must rely on large individual biopharmaceutical companies to import the drugs on their behalf, which leaves small to mid-sized clients with less options. This new license helps George Clinical become a one-stop shop—highly competitive provider for sponsors looking to add Taiwan to their portfolio of clinical trial locations.
CROs must hold a wholesale drug license to manage an investigational medicinal product (IMP) in a clinical trial. Now that George Clinical possesses this license, it can manage drug importation for both renewals and amendments, IMP stock management, relabeling, return and destruction.
George Clinical is a leading mid-market, regional CRO with a focus in Asia-Pacific. With over 20 years of experience and more than 300 staff covering 38 geographic locations throughout the USA, Asia-Pacific and Europe, George Clinical provides the full range of clinical trial services to biopharma, medical device and diagnostic customers, for all trial phases, registration and post-marketing trials.
Based in Australia, George Clinical has managed more than 40,000 patients in trials across more than 1,700 research sites. Its parent organization, The George Institute for Global Health, is a leading chronic disease research institution.
George Clinical represents an interesting model given its unique ownership and regional background yet global capability. As the CRO market becomes more consolidated (e.g. the top 5 to 10 CROs control over 50% of the revenues) small to mid-sized assets (with global scale) become valuable to consider for sponsors of all types.Source: PR Newswire